News
Eli Lilly says new GLP-1 weight loss pill could reach market in 2026
Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,
Eli Lilly (LLY) raised its full-year forecast after beating second quarter expectations, but shares slipped as its ...
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.
Eli Lilly (NYSE:LLY) is set to report Q2 earnings on Thursday, August 7, before the market opens, with Wall Street closely ...
Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...
19hon MSN
Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...
Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback